ClinicalTrials.gg
RecruitingNCT07027748Updated Jul 14, 2026

Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

A Phase 1 interventional study of Naxitamab and Irinotecan in Neuroblastoma, Neuroblastoma Recurrent and Relapsed Neuroblastoma, sponsored by Steven DuBois, MD. Recruiting at 2 sites in United States. Open to participants aged 1 Year to 30 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Steven DuBois, MD · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
1 Year to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies testing naxitamab in Neuroblastoma — 9 open to participants now, 12 under way, none of them phase 3. naxitamab · Neuroblastoma.

Planned enrollment
14th of 17
18 · median 62
Started
2025
the only one that year
Phase 1
4 of 17
1 open now
Primary completion
2027-07
later than 6 of 11 live
Registered
15th of 17
by date
Lead sponsor
1 of 17
Steven DuBois, MD

Among the 17 studies testing naxitamab in Neuroblastoma, this one is the 14th largest by planned enrollment, is the only one that started in 2025, is one of 4 in phase 1, reaches primary completion later than 6 of the 11 other live ones, and was the 15th registered.

Neuroblastoma

676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.

Browse Neuroblastoma studies →

Open to participants now

9 of the 17 studies testing naxitamab in Neuroblastoma are open now, in 7 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About naxitamab

naxitamab: first FDA approval 2020 (DANYELZA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.

This study: 1 Year to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing naxitamab in Neuroblastoma, or all of them as a file.
02

Study summary

This research is being done to investigate a treatment regimen of Irinotecan, Temozolomide, and Sargramostin, and an immunotherapy called Naxitamab and whether giving Naxitamab more slowly reduces the side effects for participants with relapsed or refractory neuroblastoma.

The name of the study drugs involved in this study are:

  • Naxitamab (A type of monoclonal antibody)
  • Irinotecan (A standard of care chemotherapy)
  • Temozolomide (A standard of care chemotherapy)
  • Sargramostim (A standard of care, granulocyte-macrophage colony stimulating factor)
Read the detailed description

This phase 1, single treatment arm, prospective trial is designed to identify the maximally safe infusion duration of Naxitamab in combination with Irinotecan, Sargramostim, and Temozolomide for participants with relapsed, refractory, progressive neuroblastoma. Study doctors are studying different Naxitamab infusion duration levels (how quickly the drug is given into the vein) to determine if this makes a difference in side effects such as pain or infusion reactions.

Not every participant in this research study will receive the same infusion duration of the study drug, Naxitamab. The infusion duration received will depend on the number of participants who have been enrolled in the study and how well an infusion duration is tolerated.

The duration groups will be as follows:

  • Duration Level -1: Naxitamab infusion duration will be 5 hours
  • Duration Level 1: Naxitamab infusion duration will be 4 hours
  • Duration Level 2: Naxitamab infusion duration will be 3 hours

The U.S. Food and Drug Administration (FDA) has approved Naxitamab for patients aged greater than 1 year with relapsed/refractory neuroblastoma in the bone or bone marrow.

The research study procedures include screening for eligibility, in-clinic visits, questionnaires, blood tests, Computerized Tomography (CT) scans, Magnetic Resonance Imaging (MRI) scans, or Meta-Iodine odobenzylguanidine (MIBG) scans, echocardiograms (ECGs), bone marrow aspiration/biopsies.

It is expected that about 18 people will take part in this research study.

YmAbs Therapeutics is supporting this research study by providing naxitamab for the trial and support to measure naxitamab blood levels.

03

Conditions studied

  • Neuroblastoma
  • Neuroblastoma Recurrent
  • Relapsed Neuroblastoma
  • Refractory Neuroblastoma

Browse trials for

Keywords

  • Neuroblastoma
  • Neuroblastoma Recurrent
  • Relapsed Neuroblastoma
  • Refractory Neuroblastoma
  • Progressive Neuroblastoma
04

Who can participate

Ages eligible
1 Year to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic Diagnosis: Patients must have had histologic verification of neuroblastoma or ganglioneuroblastoma or demonstration of neuroblastoma cells in the bone marrow with elevated urinary catecholamines [i.e. > 2 x (ULN)], at the time of initial diagnosis.
  • Disease Patients must have ONE of the following:

    • 1) Any prior episode of recurrent high-risk disease following completion of frontline high-risk therapy. Patients may have received other for treatment of recurrent disease prior to enrolling to this trial.
    • 2) Prior progressive high-risk disease during frontline high-risk therapy. Patients may have received other lines of therapy for treatment of progressive disease prior to enrolling to this trial.
    • 3) Primary resistant/refractory disease (less than partial response by INRC) detected after the conclusion of at least 4 cycles of aggressive multidrug induction chemotherapy on or according to a high-risk neuroblastoma protocol (examples include ANBL0532, ANBL09P1, ANBL12P1, ANBL1531, ANBL2131) that was treated with additional therapy with the goal of improving remission status prior to enrolling to this trial.
  • Documentation of Disease: Patients must have at least ONE of the following at the time of enrollment:

    • 1) Measurable tumor on MRI or CT scan. Measurable is defined as ≥ 10 mm in at least one dimension (or 15 mm in short axis for lymph node) on spiral/helical CT or MRI that is MIBG avid or demonstrates increased FDG uptake on PET scan.
    • 2) MIBG-avid lesion detected on MIBG scan with positive uptake at a minimum of one site. This site must represent disease recurrence or known refractory disease at a site not previously radiated.
    • 3) In patients with known MIBG non-avid disease, FDG-avid lesion detected on FDG- PET scan with positive uptake at a minimum of one site. This site must represent disease recurrence or known refractory disease at a site not previously radiated.
    • Of note, patients with isolated bone marrow only disease are NOT eligible for this trial.
  • Prior Therapy: Prior lines of anticancer therapy allowed as described in eligibility section above by disease status. from prior therapy are as follows:

    • Myelosuppressive chemotherapy: Last dose given 14 days prior to enrollment.
    • Small molecule targeted therapies (anti-neoplastic agents including retinoids): Last dose given 7 days prior to enrollment.
    • Monoclonal antibodies: Last given at least 7 days or 3 half-lives, whichever is longer, prior to enrollment.
    • Radiation:

      • Craniospinal irradiation: Last fraction received minimum of six weeks prior to enrollment
      • All other radiation: Last fraction received minimum of 14 days prior to enrollment
    • Hematopoietic stem cell transplant: Date of autologous stem cell infusion following myeloablative chemotherapy must have been a minimum of 12 weeks prior to enrollment. Patients are not eligible post stem cell transplant.
    • Cellular therapies (including CAR-T cells, NK cells, other related cellular therapies): 21 days from the last cellular therapy infusion prior to enrollment and recovery from all associated toxicities
    • 131I-MIBG therapy: Last therapy received a minimum of 6 weeks prior to enrollment.
  • Age: Patients 1 - 30 years of age at the time of enrollment are eligible for this study.
  • Performance level: Patients must demonstrate adequate performance level as measured by ≥ 70% for patients aged 16 years or older, OR Lansky ≥ 70% for patients younger than 16 years. Please see Appendix A for performance score measurement.
  • Participants must meet the following organ and marrow function as defined below:
  • Adequate bone marrow function as defined as BOTH of the following:

    • Peripheral (ANC) ≥ 750/uL. Must be more than 14 days from last administration of long-acting myeloid stimulating factor (e.g. pegfilgrastim) or 7 days from last administration of short- acting myeloid stimulating factor (e.g. filgrastim or sargramostim)
    • Peripheral count ≥ 75,000/uL. Must be without support, defined as at least 7 days from last platelet transfusion and/or platelet stimulating agent.
  • Adequate renal function as defined as EITHER of the following:

    • Radioisotope ≥ 70ml/min/1.73 m2
    • Serum creatinine based on age/sex as follows:
    • Age Maximum Serum Creatinine (mg/dL)

      • 1 to \< 2 years Male 0.6 Female 0.6
      • 2 to \< 6 years Male 0.8 Female 0.8
      • 6 to \< 12 years Male 1.0 Female 1.0
      • 12 to \< 13 years Male 1.2 Female 1.2
      • 13 to \< 16 years Male 1.5 Female 1.4

        ---≥ 16 years Male 1.7 Female 1.4

      • The threshold creatinine values in this Table were derived from the Schwartz formula for estimating GFR.
  • Adequate liver function defined as ALL of the following:

    • Total ≤ 1.5 x ULN for age*
    • ≤ 3.0 x ULN for age (≤ 135 U/L). For the purpose of this study, the ULN for ALT is 45 U/L
    • Albumin > 3 g/dL --*If patient has known Gilbert syndrome, direct bilirubin should be used to measure liver function instead of total bilirubin. Direct bilirubin must be within normal limits for age for these patients.
  • Adequate cardiac function measured by echocardiogram as defined as EITHER of the following:

    • Shortening fraction of ≥ 27%
    • of ≥ 50%
  • Adequate blood pressure as defined by BOTH of the following:

    • Patients must have \< Grade 2 hypertension AND
    • Be on no more than one standing antihypertensive
  • Adequate pulmonary function: Patients must have adequate pulmonary function, defined as:

    • No dyspnea at rest
    • No exercise intolerance
    • Room air O2 saturation >94%
    • Not on chronic oxygen therapy
  • Adequate pancreatic function, defined as lipase \< 1.5 x ULN
  • Able to comply with protocol requirements
  • Adequate : The effects of naxitamab on the developing human fetus are unknown. For this reason and because other therapeutic agents used in this trial are known to be teratogenic, participants with potential to become pregnant or to impregnate a partner must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a participant become pregnant or suspect they are pregnant while they or their partner is participating in this study, they should inform the treating physician immediately. Patients treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of protocol therapy.
  • Ability to understand and/or the willingness of their parent or legally authorized representative to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Chronic (more than 2 weeks duration) diarrhea > grade 1
  • Prior receipt of naxitamab
  • Untreated central nervous system (CNS) disease
  • Pregnant or currently breast feeding: Pregnant participants are excluded from this study because protocol therapy has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the parent with protocol therapy, participants planning to continue breastfeeding are excluded from the study.
  • arrhythmias, i.e. those that cause clinical symptoms or require medications for control of symptoms
  • Prior allergic reaction to irinotecan or temozolomide
  • Discontinuation of prior irinotecan or temozolomide due to unacceptable toxicity
  • Discontinuation of prior GD2 directed immunotherapy due to unacceptable toxicity other than allergic reaction
  • Serious intercurrent illness
  • Active uncontrolled infection
  • Existing major organ dysfunction >Grade 2, except for hearing loss and hematological status, kidney, and liver function as described in eligibility criteria
  • Concomitant Medication Restrictions:

    • Patients may not be receiving medications including pharmacologic doses of or immunomodulatory agents due to concern for inhibition of antibody effect. Local and inhaled steroid agents are permitted.
    • Patients may not be receiving concurrent anti-cancer agents or radiotherapy.
    • Patients may not have received valproic acid within 14 days prior to enrollment.
    • Patients may not have received strong inducers, strong CYP3A4 inhibitors, or strong UGT1A1 inhibitors within 14 days prior to enrollment.

      • Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/ procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Naxitamab Infusion+ Ironotecan + Temozolomide + Sargramostim

    Participants will be enrolled in a modified 3+3 design to establish a maximum tolerated, infusion duration for Naxitamab. Dosage will start at Duration Level 1 and will de-escalate to Duration Level -1 or escalate to Duration Level 2 according to dose-limiting toxicity (DLT) criteria. * Baseline visit * Cycle 1 (21 day cycle): * Days 1, 3, and 5: Predetermined dose of Naxitamab 1x daily * Days 1 through 5: Predetermined dose of Temozolomide 1x daily * Days 1 through 5: Predetermined dose of Ironotecan 1x daily * Days 6 through 12: predetermined dose of Sargramostim 1x daily * Cycles 2 through 6 (21 day cycles): * Imaging on Cycles 2, 4, and 6 * Days 1, 3, and 5: Predetermined dose of Naxitamab 1x daily * Days 1 through 5: Predetermined dose of Temozolomide 1x daily * Days 1 through 5: Predetermined dose of Ironotecan 1x daily * Days 6 through 12: predetermined dose of Sargramostim 1x daily * End of treatment visit * Follow up at 1 year post-treatment

    Drug: Naxitamab · Drug: Irinotecan · Drug: Temozolomide · Drug: Sargramostim granulocyte-macrophage colony stimulating factor

Interventions

  • Recombinant humanized anti-GD2 monoclonal antibody, single-use vial, via intravenous (into the vein) infusion per protocol.

  • Topoisomerase Inhibitor, single-dose vial, via intravenous infusion per standard of care

  • Alkylating agent, capsule, via orally (by mouth) per standard of care

    Also known as: Temodal, Temodar

  • DrugSargramostimStudies of SargramostimSargramostim pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF), multi-use vial, via subcutaneously (under the skin) injection per standard of care

    Also known as: Leukine

06

What researchers measure

Primary outcomes

  1. Recommended duration of naxitamab infusion

    The duration of naxitamab infusion that is safe and tolerable will be measured using the endpoint of an occurrence of any dose limiting toxicity. A modified 3+3 design will be used, where the 'modification' permits a single duration level de-escalation in addition to the typical duration group level escalation.

    Time frame: Assessed at the end of the first cycle of treatment, where 1 cycle is 21 days

Secondary outcomes

  1. Frequency of severe infusion related pain as measured by NCI Common Terminology Criteria for Adverse Events (CTCAE)

    Frequency of CTCAE severe infusion related pain is defined as the count of all participants that experience a grade 3 or higher pain event as measured by CTCAE version 5.

    Time frame: Assessed days 1 and 8 for Cycles 1 through 6, where 1 cycle is 21 days

  2. Frequency of severe infusion related pain as measured by the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PEDS PRO-CTCAE)

    Frequency of PEDS PRO-CTCAE severe infusion related pain is defined as the count of all participants that experience a score of 3 or greater on Question 1b of the PRO-CTCAE instrument.

    Time frame: Assessed days 1 and 8 for Cycles 1 through 6, where 1 cycle is 21 days

  3. Frequency of grade 3 or higher infusion related pain as measured by The Face, Legs, Activity, Cry, and Consolability (FLACC) Scale

    Frequency of FLACC severe infusion related pain is defined as the count of all participants that experience a score of 7 or greater on the FLACC scale instrument.

    Time frame: Assessed on every naxitamab infusion day (days 1, 3, and 5) for both Cycle 1 and 2, where 1 cycle is 21 days

  4. Frequency of grade 3 or higher infusion related pain as measured by the Wong-Baker FACES scale

    Frequency of FACES severe infusion related pain is defined as the count of all participants that experience a score of 4 or greater on the Wong-Baker FACES instrument.

    Time frame: Assessed on every naxitamab infusion day (days 1, 3, and 5) for both Cycle 1 and 2, where 1 cycle is 21 days

  5. Frequency of grade 3 or higher related pain as measured by the Numeric Rating Scale (NRS)

    Frequency of NRS severe infusion related pain is defined as the count of all participants that experience a score of 7 or greater on the Numeric Rating Scale (NRS) instrument.

    Time frame: Assessed on every naxitamab infusion day (days 1, 3, and 5) for both Cycle 1 and 2, where 1 cycle is 21 days

  6. Frequency of additional infusion-related toxicity

    Frequency of additional infusion-related toxicity will be defined as the count of toxicities which necessitate additional supportive care or interventions (i.e. an outpatient that requires hospital admission; an inpatient that requires ICU transfer).

    Time frame: Assessed at each clinic visit throughout the duration of treatment and for 35 days following the last dose of treatment, approximately 161 days

  7. Overall Best Response

    Overall best response (as defined per International Neuroblastoma Response Committee criteria) at or before the end of 6 cycles of protocol chemoimmunotherapy.

    Time frame: Assessed at the end of 6 cycles of protocol chemoimmunotherapy, approximately 126 days

  8. Progression-Free Survival (PFS)

    PFS time, defined as time from first response until first occurrence of relapse, progression, or death due to disease. Participants without an event will be censored at the time of last contact.

    Time frame: Assessed quarterly until withdrawal of consent or completion of the study (1 year follow-up after last treatment dose given to last enrolled patient).

  9. Overall Survival (OS)

    OS time, defined as the time from first study treatment to death due to any cause, or censored at date of last contact.

    Time frame: Assessed quarterly until withdrawal of consent or completion of the study (1 year follow-up after last treatment dose given to last enrolled patient).

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.

Of 73 non-industry phase 1 interventional studies under Neuroblastoma, half reached primary completion within 89 months of starting (the median), counting those still running; a quarter within 65 and three quarters within 117. This study's planned 24 months is below that.

Counting every sponsor, half of 86 studies reached it within 83 months; a quarter within 60 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2025
First posted
Jun 18, 2025
StartActual
Jun 27, 2025
Primary completionEst.
Jul 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07027748
Lead sponsor
Steven DuBois, MD
Collaborators
Y-mAbs Therapeutics
Responsible party
Steven DuBois, MD (Sponsor-Investigator, Dana-Farber Cancer Institute) — Sponsor-investigator
First posted
Jun 18, 2025
Start date
Jun 27, 2025
Primary completion
Jul 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Jul 14, 2026

Study contacts

Steven DuBois, MD, MS
Contact
Steven_Dubois@dfci.harvard.edu
617-632-5460
Steven DuBois, MD, MS
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Naxitamab · Irinotecan · Temozolomide

Start the discussion